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Purpose: To assess the benefits of aggressive chemoradiation therapy followed by
surgery in resectable esophageal carcinoma.
Method: Twenty-nine patients with resectable carcinoma were treated with 60 Gy of
radiation (2 Gy daily for 6 weeks) and concurrent chemotherapy consisting of
continuous infusion of 5-fluorouracil (200-225 mg/m2/d), paclitaxel (25, 40, 50, or
60 mg/m2) weekly over 1 hour, and cisplatin (25 mg/m2) weekly immediately
following paclitaxel throughout radiation. Patients received either 4 cycles of
postoperative paclitaxel 175 mg/m2 over 3 hours and cisplatin 75 mg/m2 every 3
weeks or paclitaxel 175 mg/m2 over 3 hours and cisplatin 75 mg/m2 every 3 weeks
prior to the initiation of chemoradiation. After induction therapy and restaging,
esophagectomy was performed 4 to 6 weeks later.
Results: Twenty-seven patients were eligible for study (26 men, 23 with adenocarci-
noma). Median age was 58 years (range 30-73). The maximum tolerated dose combi-
nation was paclitaxel 50 mg/m2 over 1 hour weekly, cisplatin 25 mg/m2 over 1 hour
weekly, 5-fluorouracil 200 mg/m2/d by continuous infusion throughout radiotherapy and
radiation to 60 Gy. Twenty-two patients completed therapy and underwent surgical
resection. Four patients had complete pathological responses and 18 had partial re-
sponses with no mortality. The commonest dose-limiting toxicity was mucositis and
esophagitis (n 7). Median follow-up of 27 patients was 150 weeks (range 7-303). At
2-year follow-up 16/27 (59%) were alive and 15/27 (56%) were free of disease. At
4-year follow-up 12/27 (44%) were alive and free of disease. Median follow-up of 22
patients undergoing esophagectomy was 205 weeks (range 26-303). At 4-year follow-up
10/22 (45%) were alive and free of disease. For the 18 patients treated at or above the
maximum tolerated dose, median follow-up was 151 weeks (range 35-206) and at
3-year follow-up 9/18 (50%) were alive and free of disease.
Conclusion: Aggressive combined modality therapy of esophageal carcinoma was
associated with excellent long-term survival in this phase I trial.
Though relatively uncommon, the incidence of carcinoma of theesophagus continues to increase. This increase is in part related tothe significant increase in the number of patients presenting withadenocarcinomas secondary to gastroesophageal reflux disease andBarrett’s epithelium. Approximately 12,000 Americans will developcarcinoma of the esophagus in the coming year. Overall results of
surgery and radiation have been poor, and although surgery remains the standard of
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care for patients with resectable disease, median survival
remains less than 10 months and those presenting with
pathologic stage II (T2N0M0, T3N0M0, T1N1M0,
T2N1M0) and those with stage III (T3N1M0, T4N0-1M0)
disease have 5-year survivals of only 34% and 15%, respec-
tively. Several authors have demonstrated overall 5-year
survivals with surgery alone ranging from 33% to 52%.1-3
Rice and colleagues4 have identified 5-year survivals of
69% and 12% with surgery alone in patients with N0 and
N1 disease, respectively, and 5-year survivals of 37% in
patients who had received induction chemoradiation therapy
for N1 disease that had been downgraded to N0 disease.
Although recent randomized clinical trials have shown that
preoperative chemotherapy and radiation therapy can en-
hance surgical outcomes, the majority of patients still re-
lapse and die of their disease.5
A phase III trial by Herskovic and colleagues6 compared
combined chemotherapy and radiation with radiation alone
and showed a 26% survival advantage with combination
therapy at 5 years. However, several phase II studies utiliz-
ing preoperative concurrent chemotherapy in patients with
potentially resectable disease have shown variable re-
sponses with median survival ranging from 11 to 31 months
and 2-year survival between 37% and 58%.7,8 Later studies
using these same protocols have failed to show any benefit
with the addition of chemoradiotherapy.9 In an attempt to
improve upon these results we embarked upon a protocol
utilizing high-dose radiation together with an intensive che-
motherapy regimen followed by surgery.
Cisplatin and 5-fluorouracil have long been recognized
as having activity in esophageal carcinoma. Paclitaxel has
significant antitumor activity in epidermoid carcinomas and
adenocarcinomas originating in the esophagus and is the
most active single agent in the treatment of metastatic
esophageal cancer.10,11 Several centers have evaluated pac-
litaxel in esophageal cancer in fixed doses as preoperative
induction combination chemotherapy with cisplatin and
5-fluorouracil in addition to chemoradiotherapy (45 Gy) and
in a phase I and II trial of induction chemotherapy at 3
dosage levels of paclitaxel with cisplatin and 5-fluorouracil
and concurrent hyperfractionated radiotherapy (45 Gy to the
mediastinum, 58.5 Gy to the tumor).12,13 The rationale for
preoperative therapy stems in part from work done by
Goldie and Coldman,14 which suggests a direct relationship
between tumor burden and resistance to chemotherapy and
a possible benefit to early systemic chemotherapy. This
might be especially true for carcinomas of the esophagus
where the lack of adventitia and a rich lymphatic supply
make for early and extensive local growth and metastasis. It
is possible that chemotherapeutic agents capable of func-
tioning as a radiosensitizer as well as having activity against
systemic micrometastasis could potentially result in im-
proved survival.
In this phase I feasibility trial, escalating weekly doses of
paclitaxel were administered in conjunction with daily con-
tinuous-infusion 5-fluorouracil, weekly cisplatin, and 60 Gy
of radiation. The aim of this trial was to assess the feasibility
and toxicity of such a treatment regimen and to determine
the maximum tolerated dose of paclitaxel administered by
1-hour infusion when combined with 5-fluorouracil, cispla-
tin, and high-dose external beam radiation (60 Gy). Other
objectives were to assess the pathologic complete response
at surgery and to evaluate the progression-free and overall
survival. The interim results of this phase I protocol have
been previously reported.15 In this contribution we review
the results, as well as the long-term follow-up of all patients
treated on protocol.
Patients and Methods
Eligibility Criteria
Between January 1995 and April 1997, 29 patients were treated on
protocol approved by the Institutional Review Board at Fox Chase
Cancer Center. Tumors included histologically confirmed epider-
moid cancer or adenocarcinoma of the esophagus, including the
gastroesophageal junction. Patients required an Eastern Coopera-
tive Oncology Group performance status of 0 to 2 and normal bone
marrow, kidney, and liver function. Patients were required to have
resectable disease and had to agree to proceed with surgery if
disease was deemed resectable at the conclusion of combination
therapy. Patients were required to have disease that was identifi-
able by abnormal thickening of the esophagus and nodal enlarge-
ment on computed tomography (CT) scan and by bulky disease on
routine endoscopy. Esophageal ultrasonography was utilized in the
minority of instances because of lack of availability to confirm the
extent of intramural disease. Tis and early T1 lesions were ex-
cluded from consideration and underwent primary resection. Pa-
tients who declined this protocol were treated off protocol with
induction chemoradiation utilizing cisplatin and continuous 5-flu-
orouracil concurrent with 45 Gy radiotherapy. All patients were
required to be older than 18 years of age and were required to sign
informed consent. Patients were ineligible if they (1) had received
prior chemotherapy, thoracic radiotherapy, or surgical resection of
the esophageal tumor; (2) had biopsy-proven invasion of the
tracheobronchial tree or a tracheoesophageal fistula as demon-
strated by bronchoscopy or endoscopy; or (3) had cervical malig-
nancy.
Staging prior to induction therapy was determined by clinical
assessment including CT scans of the chest, abdomen, and pelvis
and bone scan. Due to the infrequent use of endoscopic esophageal
ultrasound, laparoscopy, and thoracoscopy, their role in staging
was not assessed. Bronchoscopy was performed routinely in upper
thoracic lesions.
Treatment Schema
Radiotherapy was delivered with the aid of a 6-MeV linear accel-
erator in daily fractions of 2 Gy for 5 days of each week for 6
weeks to a total dose of 60 Gy. The total dose delivered to the
regional nodal areas was 40 Gy and the total dose delivered to the
tumor was 60 Gy. For tumors above the carina, supraclavicular and
mediastinal nodes were targeted and for tumors below the carina,
Goldberg et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery ● Volume 126, Number 4 1169
G
TS
mediastinal and celiac nodes were included. Tumors of the gas-
troesophageal junction required treatment to the celiac nodes and
mediastinum. The cone down volume included all grossly involved
sites and included the primary tumor and grossly involved lymph
nodes with a 2.5-cm margin. The total dose to the spinal cord
should be less than 46 Gy. The maximum allowed deviation of
dose along a field was 10% and for deviation of greater than 10%
an anterior tissue compensator was used.
Concurrent preoperative chemotherapy consisted of continuous
infusion 5-fluorouracil and weekly cisplatin and paclitaxel admin-
istered throughout the duration of radiation therapy. 5-Fluorouracil
was administered at 225 mg/m2/d by continuous infusion with the
aid of an external pump device. Owing to toxicities the dose of
5-fluorouracil was later amended to 200 mg/m2/d. Paclitaxel was
administered weekly over 1 hour through the duration of radiation.
Successive cohorts received doses of 25, 40, 50, and 60 mg/m2.
The preoperative and postoperative doses and the escalation
schema for this study are shown in Table 1. All patients were
premedicated with H1 and H2 blockers, as well as steroids. Cis-
platin, at a dose of 25 mg/m2, was administered weekly throughout
radiation and immediately following paclitaxel. Patients received
adequate prehydration prior to cisplatin therapy. Toxicity was
scored using the common toxicity criteria. Dose-limiting toxicity
was defined as a grade 3 or grade 4 condition lasting more than 1
week. Complete blood counts were done weekly. For absolute
neutrophil counts of less than 1500 and platelet counts of less than
100,000, both radiation and chemotherapy were withheld. Cispla-
tin therapy was discontinued for creatinine rises of greater than 2.0
mg%. Initially patients who were eligible for surgery were to
receive 4 cycles of postoperative adjuvant chemotherapy. This
took the form of paclitaxel (175 mg/m2 over 3 hours) and cisplatin
(75 mg/m2) administered every 3 weeks for a total of 4 cycles.
Initially patients received postoperative chemotherapy relating to
the originally proscribed protocol. Although the majority of sur-
gical patients (15/22) received adjuvant therapy, only 3 of the
patients tolerated more than 1 cycle of adjuvant therapy. Therefore
the protocol was amended to 2 cycles of upfront therapy in the
form of paclitaxel (175 mg/m2 over 3 hours) and cisplatin (75
mg/m2) every 3 weeks. This was administered prior to initiation of
combined chemoradiation therapy in the remaining 7 patients
(Figure 1).
Following the completion of combined chemoradiation patients
underwent repeat staging evaluation with CT scans of the chest,
abdomen, and pelvis and barium swallow and upper gastrointes-
tinal endoscopy. If resectable, surgery was carried out 4 to 6 weeks
after combination therapy. The interval from randomization to
operation ranged between 10.4 and 16.3 weeks (average 12.6
weeks, median 12.3 weeks). Total or near total esophagectomy
was undertaken by 1 of the following procedures (1) Ivor Lewis
esophagectomy with high intrathoracic anastomosis above the
level of the azygous vein; (2) left thoracoabdominal, subtotal
thoracic esophagectomy; (3) complete thoracic esophagectomy
with gastric interposition and a cervical anastomosis; (4) transhi-
atal esophagectomy for lesions below the carina. Negative, prox-
imal, distal, and radial margins were obtained microscopically in
all patients. Abdominal lymphadenectomy included both gastrodu-
odenal and celiac lymph nodes. A mediastinal lymphadenectomy
was included with patients undergoing thoracotomy, and with
transhiatal resections, an attempt was made to remove all medias-
tinal lymph nodes to the level of the carina.
Assessment of Response and Follow-up
Clinical complete response was the complete disappearance of all
clinically apparent disease. Clinical partial response referred to a
greater than or equal to 50% decrease in tumor size without the
appearance of new areas of malignant disease for at least 4 weeks.
Surgical specimens were pathologically assessed for response
at multiple levels longitudinally and circumferentially. Margins
and lymph nodes were assessed with respect to both the gross and
microscopic presence of carcinoma.
Following surgery, patients were seen in follow-up every 3
months for 2 years and thereafter every 6 months. CT scans of the
chest, abdomen, and pelvis were obtained every 6 months or as
clinically indicated. Barium swallow was repeated at 6 months and
then as clinically indicated.
Statistical Considerations
Survival and time to progression were measured from initiation of
therapy. Estimates of survival and time to progression were de-
rived by the Kaplan-Meier method.16
Results
Between 1995 and 1997, 29 patients were treated on pro-
tocol. Two patients with stage IV disease at presentation
agreed to receive the combined modality phase of the study
treatment to provide additional information with respect to
its tolerability. Twenty-seven patients were deemed poten-
tially resectable with stage I-III disease and the remainder of
this analysis will focus on these 27 patients. Of the 27
patients, 26 were men and 1 was a woman. Twenty-three
patients had adenocarcinomas, 3 patients had squamous
carcinomas, and 1 had an adenosquamous carcinoma. Eight
patients had an Eastern Cooperative Oncology Group per-
formance status of 0 and 17 patients had a performance
status of 1. The median age at diagnosis was 58 years (range
30-73). The maximal tolerated dose combination was pac-
litaxel 50 mg/m2 over 1 hour weekly, cisplatin 25 mg/m2
over 1 hour weekly, 5-fluorouracil 200 mg/m2/d by contin-
uous infusion through the duration of radiation therapy, and
TABLE 1. Preoperative or postoperative chemotherapy
dosages (eligible patients)
No. of
patients
Dose of
paclitaxel*
Dose of
cisplatin*
Dose of
5-FU†
A 4 25 25 225
A 5 40 25 225
A 7 60 25 225
A 5 5 25 200
B 6 50 25 200
A, Postoperative adjuvant chemotherapy; B, preoperative combined-mo-
dality therapy; 5-FU, 5-fluorouracil.
*Concurrent with XRT; given weekly over 1 hour.
†Concurrent with XRT; given by daily intravenous infusion.
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radiation to 60 Gy. Twenty-two of 27 patients completed
therapy and underwent surgical resection of disease (20
adenocarcinoma, 1 squamous carcinoma, 1 adenosquamous
carcinoma). Of the 5 patients who did not undergo surgical
resection, 1 patient died as a result of sepsis at the conclu-
sion of therapy, 1 had progressive disease following com-
pletion of therapy, 2 patients refused, and 1 patient had
worsening of preoperative lung function that precluded sur-
gery. Four of these patients were appointed to the protocol
that required postoperative chemotherapy. Paclitaxel was
given in the doses of 25 mg (n  1), 40 mg (n  1), 50 mg
(n  1), and 60 mg (n  1) prior to operative eligibility.
Only the fifth patient was appointed to the final protocol that
eliminated adjuvant therapy and received a dose of pacli-
taxel (175 mg) with cisplatin as induction to combined
chemoradiation therapy (paclitaxel 50 mg). Of the 22 pa-
tients who went to surgery there were 4 complete patholog-
ical responses (18%). Of 11 patients who were pretreated at
the maximal tolerated dose (MTD), there were 3 complete
pathological responses (27%) and 8 incomplete responses
(73%). There were no postoperative mortalities.
Dose-limiting (World Health Organization grades 3 and
4) toxicities included mucositis (7 patients), esophagitis (7
patients), diarrhea (4 patients), nausea and vomiting (3
patients), neuropathy (3 patients), line infection (3 patients),
and electrolyte wasting (2 patients).
Curative resections were performed on 22 patients: tho-
racoabdominal esophagectomy in 1 patient, Ivor Lewis
esophagogastrectomy in 5 patients, and transhiatal esopha-
gectomy in 16 patients. Lymphadenectomy averaged 12.7
nodes per operative procedure with a range of 5 to 24. Nine
patients had a jejunostomy placed at initial thorascopic
staging and 13 at operative resection. Hospitalization post-
operatively averaged 15.5 days. The average blood loss per
operative procedure was 425 mL.
Postoperative complications were frequent, the most
common being fever (n  14), anemia (n  13), wound
infection (n  6), bacteremia (n  5), pneumonia (n  4),
and respiratory failure requiring intubation (n  4) (Table
2).
Preoperative stages of patients who underwent surgery
identified T1 N0 (n  1), T2 N0 (n  14), T3 N0 (n  2),
T2 N1 (n  2), and T3 N1 (n  3). In patients with either
no change or a decrease in stage after induction chemora-
diation therapy (n  12), 8 are alive and free of disease and
4 are dead. In those with an increase in stage (n 10), 2 are
alive and free of disease and 8 are dead.
Follow-up
For all potentially resectable patients (n  27) median
follow-up was 150 weeks (range 7-303). At a minimum
follow-up of 2 years 16/27 (59%) patients were alive and
15/27 (56%) were free of disease. At a minimum follow-up
of 3 years, 14/27 (52%) patients were alive and free of
disease. At a minimum follow-up of 4 years, 12/27 (44%)
patients were alive and free of disease.
Further subgroup analysis was undertaken on the 22
patients who went on to esophageal resection, as well as the
Figure 1. Treatment scheme.
TABLE 2. Postoperative complications (n  22)
Number
Fever (100.6°F) 14
Anemia requiring transfusion(s) 13
Wound infection 6
Bacteremia 5
Respiratory failure requiring intubation 4
Pneumonia 4
Urinary tract infection 3
Anastomotic leak 3
Arrhythmia 3
Postoperative ileus 3
Pleural effusion requiring thoracentesis 2
Diarrhea 2
Deep vein thrombosis 2
Psychosis 2
Depression (severe) 2
Others
Chylothorax 1
Recurrent laryngeal nerve injury 1
Intraoperative splenectomy 1
Renal failure 1
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16 patients who were treated at or above maximal tolerated
dose. Analysis of the 22 patients who underwent esopha-
gectomy reveals that median follow-up was 205 weeks
(range 26-303). At a minimum follow-up of 2 years 12 of 22
(55%) patients were alive and free of disease. At a minimum
follow-up of 3 years 11 of 22 (50%) patients were alive and
free of disease. At a minimum follow-up of 4 years, 10 of 22
(45%) patients were alive and free of disease. For the 18
patients treated at or above maximal tolerated dose, median
follow-up was 151 weeks (range 35-206). Overall median
survival and overall median disease-free survival has not
been reached. At a minimum follow-up of 2 years, 11 of 18
patients were alive and 10 of 18 were free from disease, and
at a minimum follow-up of 3 years 9 of 18 were alive and
free from disease progression. Of note, 1 patient who did
not proceed to surgery due to progressive disease (tracheal
involvement) remains alive and free of disease at 3 years
and 9 months. Of patients with progressive disease 2 pa-
tients recurred locally and 10 progressed with distant met-
astatic disease.
More frequent complete responses were identified in
patients treated at or above MTD (0/7 below vs 4/15 above)
but correlation with survival was insignificant.
Fifteen of 22 surgical patients received postoperative
chemotherapy. Because of intolerance to 2 complete cycles,
the adjuvant chemotherapy was discontinued and placed as
induction therapy prior to chemoradiation in the last 7 of 22
patients. Kaplan-Meier actuarial survival at 4 years was
42% (Figure 2).
Discussion
In this report we have presented the results of a phase I trial
aimed at assessing the feasibility of administering an ag-
gressive preoperative combined therapy regimen in patients
with potentially operable carcinoma of the esophagus. The
results of this phase I study suggest that in a select group of
patients this regimen could be administered safely. Al-
though toxicities were encountered, the majority of patients
went on to surgery and although there were significant
postoperative complications, no patients died in the periop-
erative setting.
The role of adjuvant chemotherapy in the setting of
potentially operable disease remains controversial. Initially
our patients were treated with adjuvant cisplatin and pacli-
taxel following the completion of concurrent chemoradia-
tion and surgery. As few were able to tolerate the adjuvant
regimen it was subsequently moved into the neoadjuvant
setting. This meant that not only were patients able to
receive the full regimen but more importantly it did not
prevent any patient from completing the remainder of the
protocol.
The National Comprehensive Cancer Network guide-
lines identify the use of esophageal ultrasonography and
positron-emission tomography (PET) scanning as an option
in the staging of esophageal carcinoma. Throughout most of
this study these 2 investigative procedures were not readily
available to our patients for staging purposes. Prior to an
induction therapy program, patients must be staged as effi-
ciently as possible to accurately assess response to therapy
at the time of the operative procedure. We highly recom-
mend that esophageal ultrasonography and PET scan be
included in the assessment of all patients prior to induction
therapy. They are relatively benign procedures compared
with the more invasive procedures such as a mediastinos-
copy, laparoscopy, and thoracoscopy, which we feel should
be utilized in specific instances only when indicated.
In addition to reporting the results of the phase I trial, we
have provided long-term data on patients treated on this
trial. The progression-free survival and overall survival of
patients treated on protocol suggest that an aggressive pre-
operative combined-modality therapy regimen might aug-
ment surgical outcomes in patients with potentially operable
carcinoma of the esophagus. This is especially true for
patients who had been downstaged and who subsequently
have had curative resections.
A potential criticism relates to the relatively low rate of
pathological complete responses obtained in this study. In
keeping with other investigators, we chose a benchmark of
25% pathological complete response against which to mea-
sure the efficacy of the preoperative regimen. Our patho-
logical complete response rate was 18% and we attribute
this in part to our decision to fully examine the entire
surgical specimen microscopically. Despite the relatively
low pathological complete response rate, however, long-
term follow-up on these patients suggests in impressive
median overall survival and over all disease-free survival.
The finding of residual disease in 18 of 22 surgical speci-
mens suggests that surgery remains an essential component
in the treatment of localized esophageal carcinoma.
Figure 2. Actuarial survival.
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The progression-free survival and overall survival seen
with this approach justify additional patient accrual at radi-
ation doses of 45 Gy to determine if the regimen has lesser
toxicity and comparable efficacy. Persistence of these pre-
liminary indications of improved survival will warrant pro-
spective phase III testing.
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